Set New Password

Please enter your email address below. You will receive a link to reset your password.

Enter your email address to send your request to your account manager. Contact your account manager to receive a password recovery link.

Introduction

The objective of developing a B2B portal for pharma wholesale customers / suppliers are to give them direct access to the source..

Mdez Exchange allows licensed customers / suppliers to register in to the portal by entering basic information and their licenses. Request for registration will be validated and approved.

Once the account is approved, customers will be able to upload their requirement list to their profile. They will also be able to upload the product list for which they have a license, and will be linked to their profile. The suppliers who has got access to these products will be able to see the request and will be notified about the customers requirements.

Suppliers also will be able to upload list of products available, to their profile and customers who has got license for these products will be notified.

Medz Exchange will assist PI companies to source products directly from any country of origin. Companies who are sourcing for Clinical trial can also list their requirement to reach wider audience. Pharma Importers from out side EU can source products economically. Suppliers who list their products will have certainty of sale at the best price as almost all the PI companies in the EU will be using the Medz Exchange.

Feature

• Companies with WDL can only sign up

• Once signed up WDL validation and site audit will be done prior to approval

• Customers posts their requirements on the portal

• Suppliers posts their availability on the portal

• Suppliers’ and Customers’ identity not disclosed between the parties

• Suppliers are restricted to post products only from their country of origin

• Customers are allowed to accept, reject, or give an offer for any lines available

• Suppliers will also be able to accept or reject an offer from customers

• Clinical trail companies will be able to specify the batch and other requirements

• Suppliers will be able to offer limited number of lines in the initial period

• Customers will be able to list limited number of requirements in the initial period

• Customer & suppliers will have an option to subscribe to list unlimited number of lines

• Customer & Suppliers will be able to sign up for premium membership

• Supplier will be given rating based on their past performance

• Portal will offer branded, OTC and generic products

• Able to accept Escrow payments from customers

• Portal will also accept Crypto payments

Customer Benefits

• Ability to source directly from source

• 100% of the suppliers are vetted and audited prior to approval

• Able to see product availability from various country of origin

• Able to compare prices from various countries

• Could negotiate prices with suppliers

• Will get clarity on availability and lead time

• Improves the buying efficiency & margin

• Direct access to wide range of suppliers across Europe

• Reduce the dependency on intermediaries

• Ability to keep the identity undisclosed

• Able to place orders with suppliers with good track record

Supplier Benefits

• Ability to sell products to the best buyers

• Certainty of trade being agreed with a customer

• Could negotiate prices with the customers

• Improves the selling efficiency & margin

• Access to wide range of customers across Europe & outside EU

• Ability to sell directly rather than selling through traders

• Ability to keep the identity undisclosed

• Able to sell products directly to reputable customers

• Get insight directly from customers about their current requirements

Conclusion

Symbio Farma B.V. is a Netherlands based pharmaceutical wholesaler operating across Europe and beyond. Symbio have been in wholesale distribution business for over 10 years and understand the needs of the pharmaceutical industry. Symbio has been working on systems to improve communication between all parties so that it improves availability and accessibility to drugs, reduce drug costs around Europe and raise the standards in the supply chain.